Renal & Urology News

Renal & Urology News is a digital medical news platform and a monthly printed magazine located in New York City. It provides updates on clinical information specifically for nephrologists and urologists, highlighting insights from medical conferences and articles published in peer-reviewed journals.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#1010280

United States

#326441

Health/Health Conditions and Concerns

#918

Traffic sources

Monthly visitors

Articles

Childhood Cancer Survivors at Increased Risk for Chronic Kidney Disease, Hypertension

4 days ago | renalandurologynews.com | natasha persaud

Childhood cancer survivors develop hypertension and chronic kidney disease (CKD) at a higher rate than other pediatric populations, sick or well, a recent study finds. Asaf Lebel, MD, of Ha’Emek Medical Center in Afula, Israel, and colleagues investigated the onset of hypertension or CKD up to 27 years after childhood cancer treatment using administrative health care data from Ontario, Canada. The Ontario population is ethnically diverse and has universal health care.
How Sex Hormone Therapy May Influence Kidney Physiology

5 days ago | renalandurologynews.com | natasha persaud

A prospective observational study of transgender individuals receiving sex hormones opens a window into kidney physiology.
Adding Zilebesiran to Current Hypertension Treatment Further Lowers Blood Pressure

5 days ago | renalandurologynews.com | natasha persaud

Zilebesiran added to hypertension background therapy further reduces systolic blood pressure (SBP) within 3 months, investigators report. Zilebesiran is an investigational RNA interference therapeutic that reduces angiotensinogen production.
Grade Group 1, ASAP Found on Prostate Biopsy Warrant Concern

6 days ago | renalandurologynews.com | Vicki Moore

Prostate biopsy findings of Gleason grade group (GG) 1 or atypical small acinar proliferation (ASAP) may require monitoring, according to 2 studies presented at the American Urological Association 2025 annual meeting in Las Vegas, Nevada.
Silicone-Coated Stent More Effective for Malignant Ureteral Obstruction

1 week ago | renalandurologynews.com | Ryner Lai

A silicone-covered metallic stent maintains patency better than a double-J stent in patients with malignant ureteral obstruction, according to results of a randomized controlled trial reported at the American Urological Association annual meeting in Las Vegas, Nevada. Ureteral obstruction due to tumor growth increases the risk of hydronephrosis and urinary tract infection. Prompt surgical stent implantation is crucial.
Sparsentan Under Review for Focal Segmental Glomerulosclerosis

1 week ago | renalandurologynews.com | Jaymin Kang

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (NDA) for sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS). Sparsentan, an oral endothelin and angiotensin II receptor antagonist, is currently approved under the brand name Filspari® to slow kidney function decline in adults with primary immunoglobulin A nephropathy who are at risk for disease progression.
Oral Tebipenem HBr Noninferior to IV Imipenem-Cilastatin for Complicated UTI

1 week ago | renalandurologynews.com | Jaymin Kang

Topline data were announced from a phase 3 trial evaluating tebipenem pivoxil hydrobromide (HBr) in patients with complicated urinary tract infections (cUTIs). Tebipenem HBr is an investigational oral antibiotic in the carbapenem class. The randomized, double-blind, phase 3 PIVOT-PO trial (ClinicalTrials.gov Identifier: NCT06059846) included 1690 adults aged 18 years and older with cUTI or acute pyelonephritis.
Voclosporin-Based Regimen May Achieve Deeper Proteinuria Reduction in Lupus Nephritis

1 week ago | renalandurologynews.com | natasha persaud

Voclosporin treatment can further reduce the urinary protein to creatinine ratio (UPCR) to less than 0.5 g/g in a subset of patients with lupus nephritis, investigators reported at LUPUS 2025, the 16th international congress on systemic lupus erythematosus (SLE). Although the UPCR efficacy target is less than 0.5 g/g in many trials, the disease may still be active at this threshold.
Optimal PSA Cutoff for PSA Persistence After Prostate Cancer Surgery Identified

1 week ago | renalandurologynews.com | Vicki Moore

A PSA level of 0.04 ng/mL or higher may optimally define PSA persistence in patients who have had radical prostatectomy (RP) for prostate cancer, investigators reported at the American Urological Association annual meeting in Las Vegas, Nevada. PSA persistence is associated with worse oncologic outcomes, so it is crucial to identify it early.
Vascular-Targeted Photodynamic Tx Shows 5-Year Efficacy in Intermediate-Risk Prostate Cancer

1 week ago | renalandurologynews.com | Ryner Lai

Padeliporfin vascular-targeted photodynamic (VTP) therapy for localized partial prostate gland ablation shows efficacy and safety over 48 months in patients with intermediate-risk prostate cancer. An investigator presented long-term follow-up data from the phase 2b PCM-204 trial at the American Urological Association annual meeting in Las Vegas, Nevada.